Sarepta: $612M FY2021 revenue; SRP-9001 gene therapy shows significant functional improvement in DMD study

Sarepta Therapeutics, Inc.

Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.
SRP-9001 (delandistrogene moxeparvovec): Part 2 of Study 102 met primary endpoint with NSAA improvement vs external control (p=0.0009).
No new safety signals; no treatment-related SAEs, deaths, or discontinuations in Part 2.
Company reaffirms confidence in EMBARK phase 3 global study, currently dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.